Innovative DREAM Technique Restores Intestinal and Hepatic Function in Short Bowel Syndrome

Introduction

Short bowel syndrome (SBS) is a complex clinical condition resulting from extensive surgical resection of the small intestine, leading to malabsorption, nutritional deficiencies, and intestinal failure-associated liver disease (IFALD). Patients with SBS face challenges in maintaining adequate enteral nutrition (EN) due to reduced absorptive surface area, often necessitating parenteral nutrition which carries risks of complications including liver injury. Intestinal adaptation (IA), a compensatory process involving structural and functional changes, is essential for improving nutrient absorption and clinical outcomes. However, delivering sustained enteral nutrition remains difficult post-resection, limiting IA and contributing to IFALD development.

Study Background

The current therapeutic landscape for SBS lacks interventions that effectively support complete enteral nutrition while promoting intestinal regeneration and maintaining hepatic function. The Distal Recirculation of Enteral contents Augmented Mechanically (DREAM) technique was developed to address these gaps by mechanically enhancing the recirculation of enteral contents, enabling comprehensive EN despite significant bowel resection. This novel approach aims to promote IA and restore enterohepatic signaling pathways disrupted in SBS, thereby mitigating liver damage commonly associated with intestinal failure.

Study Design

This study employed a randomized controlled design involving 20 neonatal pigs allocated into three groups: a control group receiving enteral nutrition (EN), a group subjected to a 75% small bowel resection to simulate SBS, and a DREAM intervention group undergoing resection followed by the DREAM technique. The primary outcomes evaluated included growth metrics, serum biochemical markers reflecting liver function, inflammatory cytokine profiles, intestinal morphology, barrier integrity, hepatic histology, and molecular analyses via quantitative polymerase chain reaction and RNA sequencing. Functional assessments encompassed macronutrient absorption and expression of genes involved in bile acid metabolism and gut signaling pathways.

Key Findings

The DREAM intervention significantly mitigated hepatic and intestinal injury observed in the SBS group. Key liver function parameters, including serum bilirubin (0.11 vs. 5.14 mg/dL, P = 0.0008), gamma-glutamyl transferase (23.2 vs. 114.6 IU/L, P < 0.0001), and bile acid levels (9.7 vs. 39 µmol/L, P = 0.0026) were markedly improved with DREAM compared to SBS controls.

Inflammatory cytokine levels (interferon-γ, interleukin 1β, interleukin 6) and portal vein lipopolysaccharide concentrations showed significant reductions (all P < 0.05), indicating an attenuation of systemic and intestinal inflammation.

At the intestinal level, DREAM enhanced IA as evidenced by increased linear gut density (0.38 vs. 0.209 g/cm, P < 0.0001) and improved villus-to-crypt ratio (P = 0.0026), reflecting beneficial structural adaptations. Elevated glucagon-like peptide 2 (GLP-2, P < 0.0001), a known trophic hormone, was noted, alongside restoration of key tight junction proteins occludin and E-cadherin (P < 0.001), indicating improved mucosal barrier integrity.

Liver gene expression analysis demonstrated preservation of bile salt export pump and cholesterol 7α-hydroxylase regulation (P = 0.0373 and P = 0.0034 respectively), suggesting maintenance of bile acid homeostasis. Intestinal expression of farnesoid X receptor (FXR), Takeda G-protein-coupled receptor 5 (TGR5), and epidermal growth factor (EGF) signaling pathways were reactivated (all P < 0.01), which are key pathways for nutrient sensing and mucosal repair.

Transcriptomic data confirmed upregulation of metabolic, absorptive, and immune pathways consistent with restored intestinal and hepatic function. Functionally, DREAM effluent analysis revealed more than 80% macronutrient absorption within six hours (P < 0.0001), demonstrating effective nutrient uptake despite shortened bowel length.

Expert Commentary

The DREAM technique represents a significant advancement in SBS management by addressing a fundamental limitation—suboptimal enteral nutrition delivery—that impairs intestinal adaptation and promotes liver injury. By mechanically recirculating enteral contents through the distal intestine, DREAM enhances mucosal exposure to nutrients and bile acids, crucial drivers of epithelial proliferation and enterohepatic signaling. This method appears to break the vicious cycle of malabsorption and hepatic dysfunction prevalent in SBS.

Mechanistically, the preservation of bile acid transport and signaling pathways, along with improved barrier function, underscores the tight interplay between gut health and liver function. GLP-2 elevation further supports DREAM’s role in fostering a regenerative intestinal environment. While these findings are promising, the translational relevance would require cautious validation in human clinical trials considering anatomical and physiological differences.

Limitations to consider include the neonatal pig model which, although translationally relevant, may not fully replicate adult human SBS physiology. Moreover, the study duration was relatively short; long-term outcomes on liver health and nutritional independence remain to be elucidated. Potential logistical challenges in implementing mechanical recirculation clinically also merit attention.

Conclusion

DREAM offers a novel, mechanistically informed strategy to enable complete enteral nutrition in short bowel syndrome. Its ability to promote intestinal structural and functional adaptation while preventing intestinal failure-associated liver disease addresses critical unmet needs in SBS care. This approach could reduce dependence on parenteral nutrition and its associated complications, improving patient outcomes. Further clinical evaluation is warranted to validate safety, efficacy, and feasibility in the human population.

Funding and Clinical Trials

The authors did not specify the funding sources in the available abstract. Future clinical trials are necessary to explore this innovation’s applicability in human subjects with SBS.

References

1. Mehta S, et al. Distal Recirculation of Enteral contents Augmented Mechanically (DREAM) Promotes Intestinal Adaptation and Restores Enterohepatic Signaling in Short Bowel Syndrome. Gastroenterology. 2026 Jun 10. PMID: 42269947.
2. Nightingale JMD, Woodward JM. Guidelines for management of patients with a short bowel. Gut. 2006;55(Suppl 4):iv1-iv12.
3. Buchman AL. Intestinal rehabilitation and transplantation in adults and children. Curr Gastroenterol Rep. 2008;10(1):62-68.
4. Joly F, et al. Intestinal failure-associated liver disease: pathophysiology and management. Curr Opin Gastroenterol. 2016;32(2):111-117.
5. Cherbuy C, Chang C, Westrich J, et al. Bile acids and FXR regulate murine intestinal inflammation in altered microbiota-induced models. J Clin Invest. 2015;125(11):3975-3988.